All lobbying filings

BIOMARIN PHARMACEUTICAL INC.

BIOMARIN PHARMACEUTICAL INC. filed a Q2 amendment for BIOMARIN PHARMACEUTICAL INC. on July 20, 2026.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

All filings by BIOMARIN PHARMACEUTICAL INC. · Everything BIOMARIN PHARMACEUTICAL INC. has reported

Filing · LD-2 quarterly report Q2 amendment

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$340,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Lobbyists on this filing 1

DANIEL MAYNE New on this filing

Previously held: SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING

Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARDE

Medical/Disease Research/Clinical Labs

GENERAL DISCUSSIONS REGARDING CLINICAL TRIAL MODERNIZATION

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.